We evaluated the impact of FLT3‐ITD mutation clearance and achievement of CRc or CR/CRh on survival beyond 3 years in a larger FLT3‐ITD+ R/R AML patient subset who received 20‐ to 450‐mg/day gilteritinib in the CHRYSALIS study.18 This evidence concerns the gene FLT3 and acute myeloid leukemia.